 Joshua Melson
Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 24 | 2021 | 114 | 12.080 |
Why?
| | Colonoscopy | 24 | 2021 | 76 | 7.910 |
Why?
| | Adenoma | 10 | 2021 | 48 | 6.470 |
Why?
| | Colonic Polyps | 10 | 2021 | 35 | 5.370 |
Why?
| | Early Detection of Cancer | 13 | 2020 | 91 | 4.260 |
Why?
| | Neoplasms, Second Primary | 4 | 2021 | 41 | 2.560 |
Why?
| | Capsule Endoscopy | 2 | 2021 | 5 | 1.830 |
Why?
| | Mass Screening | 7 | 2020 | 193 | 1.760 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2018 | 40 | 1.430 |
Why?
| | Adenomatous Polyps | 3 | 2017 | 7 | 1.390 |
Why?
| | Endoscopy, Gastrointestinal | 3 | 2021 | 12 | 1.380 |
Why?
| | Colon | 4 | 2018 | 146 | 1.340 |
Why?
| | DNA Methylation | 3 | 2017 | 154 | 1.240 |
Why?
| | Guideline Adherence | 2 | 2016 | 81 | 1.230 |
Why?
| | Humans | 42 | 2021 | 29841 | 1.100 |
Why?
| | Barrett Esophagus | 2 | 2020 | 19 | 1.080 |
Why?
| | Gastroenterology | 3 | 2019 | 16 | 1.040 |
Why?
| | Esophageal Neoplasms | 2 | 2020 | 60 | 1.030 |
Why?
| | Intestine, Small | 1 | 2021 | 37 | 0.910 |
Why?
| | Esophageal and Gastric Varices | 1 | 2020 | 2 | 0.890 |
Why?
| | Middle Aged | 19 | 2019 | 11053 | 0.880 |
Why?
| | Poverty Areas | 1 | 2019 | 8 | 0.830 |
Why?
| | Censuses | 1 | 2019 | 8 | 0.830 |
Why?
| | Clinical Competence | 3 | 2016 | 268 | 0.800 |
Why?
| | Alcohol Withdrawal Delirium | 2 | 2015 | 2 | 0.740 |
Why?
| | Long Interspersed Nucleotide Elements | 1 | 2017 | 2 | 0.720 |
Why?
| | Residence Characteristics | 1 | 2019 | 211 | 0.710 |
Why?
| | Cecum | 1 | 2016 | 10 | 0.700 |
Why?
| | Population Surveillance | 1 | 2018 | 125 | 0.700 |
Why?
| | Lymphoid Tissue | 1 | 2016 | 22 | 0.690 |
Why?
| | Pancreatic Neoplasms | 2 | 2020 | 172 | 0.690 |
Why?
| | Adenocarcinoma | 2 | 2019 | 233 | 0.670 |
Why?
| | Unnecessary Procedures | 1 | 2016 | 30 | 0.660 |
Why?
| | Male | 18 | 2019 | 17153 | 0.650 |
Why?
| | Aged | 15 | 2019 | 9833 | 0.640 |
Why?
| | Female | 18 | 2019 | 17657 | 0.640 |
Why?
| | Colorectal Surgery | 1 | 2015 | 7 | 0.630 |
Why?
| | Carcinoma | 1 | 2016 | 83 | 0.630 |
Why?
| | Radiography, Thoracic | 1 | 2015 | 38 | 0.620 |
Why?
| | Quality of Health Care | 1 | 2016 | 134 | 0.600 |
Why?
| | Restraint, Physical | 1 | 2014 | 23 | 0.570 |
Why?
| | Patient Transfer | 1 | 2014 | 24 | 0.570 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2013 | 18 | 0.570 |
Why?
| | Risk Factors | 5 | 2021 | 2549 | 0.540 |
Why?
| | Patient Compliance | 1 | 2015 | 201 | 0.540 |
Why?
| | Diagnostic Errors | 1 | 2013 | 48 | 0.530 |
Why?
| | Retrospective Studies | 8 | 2020 | 3303 | 0.510 |
Why?
| | Ethanol | 1 | 2014 | 137 | 0.500 |
Why?
| | Intensive Care Units | 1 | 2014 | 290 | 0.470 |
Why?
| | Critical Care | 1 | 2014 | 220 | 0.460 |
Why?
| | Practice Guidelines as Topic | 5 | 2020 | 382 | 0.450 |
Why?
| | Colectomy | 1 | 2010 | 33 | 0.450 |
Why?
| | Cohort Studies | 5 | 2018 | 1911 | 0.440 |
Why?
| | Colitis, Ulcerative | 1 | 2010 | 72 | 0.430 |
Why?
| | Prospective Studies | 4 | 2021 | 1809 | 0.420 |
Why?
| | Chi-Square Distribution | 3 | 2015 | 181 | 0.390 |
Why?
| | Intestinal Mucosa | 3 | 2020 | 232 | 0.390 |
Why?
| | Colonic Neoplasms | 2 | 2018 | 83 | 0.380 |
Why?
| | Neoplasm Staging | 5 | 2018 | 503 | 0.370 |
Why?
| | United States | 4 | 2020 | 2402 | 0.370 |
Why?
| | Hyperplasia | 2 | 2018 | 25 | 0.360 |
Why?
| | Graft vs Host Disease | 1 | 2007 | 45 | 0.360 |
Why?
| | Gastrointestinal Diseases | 1 | 2007 | 43 | 0.360 |
Why?
| | Logistic Models | 3 | 2015 | 478 | 0.360 |
Why?
| | Incidence | 3 | 2019 | 813 | 0.360 |
Why?
| | Area Under Curve | 2 | 2019 | 78 | 0.340 |
Why?
| | Esophagoscopy | 3 | 2021 | 17 | 0.330 |
Why?
| | Academic Medical Centers | 2 | 2016 | 156 | 0.290 |
Why?
| | Risk Assessment | 4 | 2020 | 794 | 0.280 |
Why?
| | Severity of Illness Index | 1 | 2007 | 1220 | 0.250 |
Why?
| | Zenker Diverticulum | 1 | 2021 | 1 | 0.240 |
Why?
| | Prognosis | 4 | 2018 | 1025 | 0.240 |
Why?
| | Endosonography | 2 | 2020 | 15 | 0.240 |
Why?
| | Gastrointestinal Transit | 1 | 2021 | 14 | 0.240 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 27 | 0.230 |
Why?
| | Pancreatitis, Chronic | 1 | 2020 | 2 | 0.230 |
Why?
| | Pancreatic Cyst | 1 | 2020 | 5 | 0.230 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2021 | 29 | 0.230 |
Why?
| | Gastroparesis | 1 | 2020 | 2 | 0.230 |
Why?
| | Treatment Outcome | 4 | 2020 | 3788 | 0.220 |
Why?
| | Magnets | 1 | 2020 | 3 | 0.220 |
Why?
| | Epithelial Cells | 2 | 2013 | 99 | 0.220 |
Why?
| | Feasibility Studies | 1 | 2021 | 273 | 0.220 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2019 | 6 | 0.220 |
Why?
| | Bariatric Surgery | 1 | 2020 | 39 | 0.210 |
Why?
| | Adult | 5 | 2018 | 9591 | 0.210 |
Why?
| | Appointments and Schedules | 1 | 2019 | 15 | 0.210 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2018 | 2 | 0.200 |
Why?
| | Precancerous Conditions | 1 | 2018 | 27 | 0.200 |
Why?
| | ROC Curve | 1 | 2019 | 154 | 0.200 |
Why?
| | Forecasting | 1 | 2019 | 129 | 0.200 |
Why?
| | Colonoscopes | 1 | 2018 | 1 | 0.190 |
Why?
| | Quality Improvement | 1 | 2020 | 169 | 0.190 |
Why?
| | Genetic Testing | 1 | 2018 | 75 | 0.190 |
Why?
| | Follow-Up Studies | 2 | 2014 | 2017 | 0.190 |
Why?
| | Referral and Consultation | 1 | 2018 | 89 | 0.180 |
Why?
| | Clinical Protocols | 2 | 2015 | 74 | 0.180 |
Why?
| | Sex Factors | 2 | 2018 | 524 | 0.180 |
Why?
| | CpG Islands | 1 | 2017 | 48 | 0.180 |
Why?
| | Aged, 80 and over | 4 | 2017 | 5016 | 0.180 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 95 | 0.170 |
Why?
| | Alcoholism | 2 | 2015 | 86 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2017 | 44 | 0.170 |
Why?
| | Brain Neoplasms | 1 | 2018 | 185 | 0.170 |
Why?
| | Portal Vein | 1 | 2017 | 46 | 0.170 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 86 | 0.170 |
Why?
| | Ultrasonography, Interventional | 1 | 2017 | 73 | 0.170 |
Why?
| | Documentation | 1 | 2016 | 26 | 0.170 |
Why?
| | Age Factors | 2 | 2018 | 912 | 0.160 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 83 | 0.160 |
Why?
| | Liver Neoplasms | 1 | 2017 | 124 | 0.160 |
Why?
| | Staff Development | 1 | 2015 | 30 | 0.160 |
Why?
| | Hospitals, Community | 1 | 2015 | 22 | 0.160 |
Why?
| | Rectal Neoplasms | 1 | 2015 | 27 | 0.160 |
Why?
| | Biopsy | 2 | 2019 | 278 | 0.150 |
Why?
| | Nursing Staff, Hospital | 1 | 2015 | 75 | 0.150 |
Why?
| | Microsatellite Instability | 1 | 2014 | 7 | 0.150 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 915 | 0.150 |
Why?
| | Case-Control Studies | 2 | 2013 | 684 | 0.150 |
Why?
| | Sensitivity and Specificity | 2 | 2013 | 592 | 0.150 |
Why?
| | Analysis of Variance | 1 | 2015 | 369 | 0.140 |
Why?
| | Patient Acceptance of Health Care | 1 | 2015 | 78 | 0.140 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2014 | 37 | 0.140 |
Why?
| | Internship and Residency | 1 | 2016 | 182 | 0.140 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 617 | 0.140 |
Why?
| | Colitis | 1 | 2013 | 33 | 0.130 |
Why?
| | Mast Cells | 1 | 2013 | 44 | 0.130 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 48 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2013 | 67 | 0.130 |
Why?
| | Macrophages | 1 | 2013 | 110 | 0.130 |
Why?
| | Time Factors | 1 | 2016 | 1894 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 162 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 869 | 0.110 |
Why?
| | Transplantation Conditioning | 1 | 2007 | 36 | 0.090 |
Why?
| | Drug Resistance | 1 | 2007 | 67 | 0.090 |
Why?
| | Diarrhea | 1 | 2007 | 54 | 0.090 |
Why?
| | Immunohistochemistry | 2 | 2019 | 497 | 0.090 |
Why?
| | Adrenal Cortex Hormones | 1 | 2007 | 99 | 0.090 |
Why?
| | Acute Disease | 1 | 2007 | 272 | 0.090 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2007 | 108 | 0.080 |
Why?
| | Transplantation, Homologous | 1 | 2007 | 283 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2007 | 167 | 0.080 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 104 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2010 | 1388 | 0.080 |
Why?
| | Apoptosis | 1 | 2007 | 290 | 0.080 |
Why?
| | Reoperation | 1 | 2010 | 911 | 0.080 |
Why?
| | Fecal Incontinence | 1 | 2005 | 9 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2005 | 229 | 0.070 |
Why?
| | Endoscopes | 1 | 2021 | 14 | 0.060 |
Why?
| | Pylorus | 1 | 2020 | 2 | 0.060 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 10 | 0.060 |
Why?
| | Gastric Emptying | 1 | 2020 | 15 | 0.060 |
Why?
| | Biopsy, Fine-Needle | 1 | 2020 | 53 | 0.060 |
Why?
| | Gastroplasty | 1 | 2020 | 28 | 0.060 |
Why?
| | Inventions | 1 | 2019 | 4 | 0.050 |
Why?
| | Epidemiological Monitoring | 1 | 2019 | 8 | 0.050 |
Why?
| | Biomedical Technology | 1 | 2019 | 9 | 0.050 |
Why?
| | Canada | 1 | 2019 | 55 | 0.050 |
Why?
| | Watchful Waiting | 1 | 2019 | 10 | 0.050 |
Why?
| | Gastric Bypass | 1 | 2020 | 55 | 0.050 |
Why?
| | Diffusion of Innovation | 1 | 2019 | 42 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 43 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2020 | 78 | 0.050 |
Why?
| | Models, Anatomic | 1 | 2019 | 68 | 0.050 |
Why?
| | Microscopy, Confocal | 1 | 2019 | 127 | 0.050 |
Why?
| | Internationality | 1 | 2018 | 26 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2018 | 105 | 0.050 |
Why?
| | Biopsy, Needle | 1 | 2018 | 119 | 0.050 |
Why?
| | Videotape Recording | 1 | 2018 | 49 | 0.050 |
Why?
| | Continental Population Groups | 1 | 2018 | 113 | 0.050 |
Why?
| | Societies, Medical | 1 | 2019 | 202 | 0.050 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 2017 | 1 | 0.050 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 2 | 0.050 |
Why?
| | Portal Pressure | 1 | 2017 | 5 | 0.050 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 232 | 0.050 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2017 | 6 | 0.050 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 18 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2018 | 106 | 0.050 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2017 | 6 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 379 | 0.050 |
Why?
| | Ethnic Groups | 1 | 2018 | 176 | 0.040 |
Why?
| | Disease Progression | 1 | 2019 | 843 | 0.040 |
Why?
| | Focus Groups | 1 | 2015 | 90 | 0.040 |
Why?
| | Educational Measurement | 1 | 2015 | 65 | 0.040 |
Why?
| | Quality of Life | 1 | 2020 | 604 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2014 | 11 | 0.040 |
Why?
| | ras Proteins | 1 | 2014 | 13 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 22 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 39 | 0.040 |
Why?
| | Age Distribution | 1 | 2014 | 115 | 0.040 |
Why?
| | Age of Onset | 1 | 2014 | 115 | 0.040 |
Why?
| | Piroxicam | 1 | 2013 | 6 | 0.030 |
Why?
| | HT29 Cells | 1 | 2013 | 10 | 0.030 |
Why?
| | Chromones | 1 | 2013 | 9 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2013 | 9 | 0.030 |
Why?
| | Tryptases | 1 | 2013 | 10 | 0.030 |
Why?
| | Morpholines | 1 | 2013 | 14 | 0.030 |
Why?
| | Anticarcinogenic Agents | 1 | 2013 | 21 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 39 | 0.030 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2013 | 41 | 0.030 |
Why?
| | Cell Movement | 1 | 2013 | 117 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 288 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2013 | 232 | 0.030 |
Why?
| | Mutation | 1 | 2014 | 445 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2013 | 376 | 0.030 |
Why?
| | Rectum | 1 | 2011 | 69 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 103 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 529 | 0.030 |
Why?
| | Signal Transduction | 1 | 2013 | 563 | 0.030 |
Why?
| | Mice | 1 | 2013 | 1805 | 0.020 |
Why?
| | African Americans | 1 | 2014 | 739 | 0.020 |
Why?
| | Psychotropic Drugs | 1 | 2005 | 29 | 0.020 |
Why?
| | Causality | 1 | 2005 | 58 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2005 | 123 | 0.020 |
Why?
| | Health Surveys | 1 | 2005 | 100 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2005 | 131 | 0.020 |
Why?
| | Comorbidity | 1 | 2005 | 555 | 0.020 |
Why?
| | Animals | 1 | 2013 | 5125 | 0.020 |
Why?
| | Chicago | 1 | 2005 | 916 | 0.010 |
Why?
| | Stroke | 1 | 2005 | 340 | 0.010 |
Why?
|
|
Melson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|